Trial Outcomes & Findings for Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) (NCT NCT01800968)
NCT ID: NCT01800968
Last Updated: 2017-02-15
Results Overview
A rank score based on time to death, time to adjudicated heart failure hospitalization, and time-averaged proportional change in NTproBNP through d180. For patients that died, the patient with the shortest time from randomization to death is assigned rank 1, the second shortest time is assigned rank 2, etc. The patient with the longest time from randomization to death is assigned rank X. For patients that did not die but had a heart failure hospitalization, the patient with the shortest time from randomization to re-admission is assigned rank X+1 and the patient with the longest time from randomization to heart failure hospitalization is assigned rank Y. For patients that did not die or have a heart failure hospitalization, increases in time-averaged proportional change in NTproBNP indicate a worse result and the largest increase is assigned rank Y+1. The patient with the largest decrease is assigned rank N, where N is the sample size.
COMPLETED
PHASE2
300 participants
Randomization to 180 days
2017-02-15
Participant Flow
Participant milestones
| Measure |
Liraglutide
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Overall Study
STARTED
|
154
|
146
|
|
Overall Study
COMPLETED
|
118
|
114
|
|
Overall Study
NOT COMPLETED
|
36
|
32
|
Reasons for withdrawal
| Measure |
Liraglutide
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Overall Study
Death
|
23
|
16
|
|
Overall Study
Lost to Follow-up
|
5
|
7
|
|
Overall Study
Withdrawal by Subject
|
7
|
9
|
|
Overall Study
Physician Decision
|
1
|
0
|
Baseline Characteristics
Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)
Baseline characteristics by cohort
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
Total
n=300 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
59.9 years
STANDARD_DEVIATION 12.9 • n=99 Participants
|
59.6 years
STANDARD_DEVIATION 12.2 • n=107 Participants
|
59.7 years
STANDARD_DEVIATION 12.5 • n=206 Participants
|
|
Sex: Female, Male
Female
|
31 Participants
n=99 Participants
|
33 Participants
n=107 Participants
|
64 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
123 Participants
n=99 Participants
|
113 Participants
n=107 Participants
|
236 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
4 Participants
n=99 Participants
|
11 Participants
n=107 Participants
|
15 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
150 Participants
n=99 Participants
|
135 Participants
n=107 Participants
|
285 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
4 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
67 Participants
n=99 Participants
|
48 Participants
n=107 Participants
|
115 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
82 Participants
n=99 Participants
|
90 Participants
n=107 Participants
|
172 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Randomization to 180 daysPopulation: All randomized subjects.
A rank score based on time to death, time to adjudicated heart failure hospitalization, and time-averaged proportional change in NTproBNP through d180. For patients that died, the patient with the shortest time from randomization to death is assigned rank 1, the second shortest time is assigned rank 2, etc. The patient with the longest time from randomization to death is assigned rank X. For patients that did not die but had a heart failure hospitalization, the patient with the shortest time from randomization to re-admission is assigned rank X+1 and the patient with the longest time from randomization to heart failure hospitalization is assigned rank Y. For patients that did not die or have a heart failure hospitalization, increases in time-averaged proportional change in NTproBNP indicate a worse result and the largest increase is assigned rank Y+1. The patient with the largest decrease is assigned rank N, where N is the sample size.
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Global Ranking of Predefined Events
|
145.5 rank
Standard Deviation 88.1
|
155.7 rank
Standard Deviation 85.3
|
SECONDARY outcome
Timeframe: Baseline to 180 daysPopulation: All randomized subjects.
Change in Left Ventricular End-Diastolic Volume Index from baseline to 180 days.
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Change in Left Ventricular End-Diastolic Volume Index
|
3.37 ml per meter squared
Standard Deviation 31.9
|
-2.91 ml per meter squared
Standard Deviation 32.04
|
SECONDARY outcome
Timeframe: Baseline to 180 daysPopulation: All randomized subjects.
Change in left ventricular end-systolic volume index from baseline to day 180.
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Change in Left Ventricular End-systolic Volume Index
|
1.16 ml per meter squared
Standard Deviation 26.2
|
-3.47 ml per meter squared
Standard Deviation 26.5
|
SECONDARY outcome
Timeframe: Baseline to 180 daysPopulation: All randomized subjects.
Change in left ventricular ejection fraction from baseline to day 180
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Change in Left Ventricular Ejection Fraction
|
1.07 percent
Standard Deviation 9.1
|
1.37 percent
Standard Deviation 10.0
|
SECONDARY outcome
Timeframe: Baseline to 180 daysPopulation: All randomized subjects.
Change in medial filling pressure baseline to day 180.
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Change in Medial Filling Pressure
|
1.12 m/sec
Standard Deviation 18.8
|
0.25 m/sec
Standard Deviation 17.8
|
SECONDARY outcome
Timeframe: Baseline to 180 daysPopulation: All randomized subjects.
Change in lateral filling pressure baseline to day 180.
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Change in Lateral Filling Pressure
|
-0.05 m/sec
Standard Deviation 12.3
|
0.39 m/sec
Standard Deviation 13.1
|
SECONDARY outcome
Timeframe: Baseline to day 30Population: All randomized subjects.
Change in 6 minute walk distance baseline to day 30
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Change in 6 Minute Walk Distance
|
50.4 meters
Standard Deviation 110.8
|
37.3 meters
Standard Deviation 99.6
|
SECONDARY outcome
Timeframe: Baseline to 90 daysPopulation: All randomized subjects.
Change in 6 minute walk distance baseline to 90 days.
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Change in 6 Minute Walk Distance
|
56.8 meters
Standard Deviation 132.7
|
38.7 meters
Standard Deviation 115.4
|
SECONDARY outcome
Timeframe: Baseline to 180 daysPopulation: All randomized subjects.
Change in 6 minute walk distance baseline to 180 days.
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Change in 6 Minute Walk Distance
|
55.7 meters
Standard Deviation 133.9
|
55.3 meters
Standard Deviation 127.2
|
SECONDARY outcome
Timeframe: Baseline to 30 daysPopulation: All randomized subjects.
Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) baseline to 30 days. The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Change in Clinical Summary Score Using the Kansas City Cardiomyopathy Questionnaire (KCCQ)
|
14.69 units on a scale
Standard Deviation 25.90
|
14.44 units on a scale
Standard Deviation 22.03
|
SECONDARY outcome
Timeframe: Baseline to 90 daysPopulation: All randomized subjects.
Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) baseline to 90 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Change in Clinical Summary Score Using the Kansas City Cardiomyopathy Questionnaire (KCCQ)
|
13.86 units on a scale
Standard Deviation 24.99
|
11.72 units on a scale
Standard Deviation 23.82
|
SECONDARY outcome
Timeframe: Baseline to day 180Population: All randomized subjects.
Change in clinical summary score using the Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline to day 180.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Change in Clinical Summary Score Using the Kansas City Cardiomyopathy Questionnaire (KCCQ)
|
13.79 units on a scale
Standard Deviation 23.83
|
13.14 units on a scale
Standard Deviation 23.60
|
SECONDARY outcome
Timeframe: Baseline to 30 daysPopulation: All randomized subjects.
Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 30 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score
|
12.98 units on a scale
Standard Deviation 23.82
|
14.01 units on a scale
Standard Deviation 20.09
|
SECONDARY outcome
Timeframe: Baseline to 90 daysPopulation: All randomized subjects.
Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 90 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score
|
14.17 units on a scale
Standard Deviation 24.46
|
10.62 units on a scale
Standard Deviation 22.48
|
SECONDARY outcome
Timeframe: Baseline to 180 daysPopulation: All randomized subjects.
Kansas City Cardiomyopathy Questionnaire (KCCQ) change in overall summary score baseline to 180 days.The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life.In the KCCQ, an overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. For each domain, the validity, reproducibility, responsiveness and interpretability have been independently established. Each question is answered by the subject on a 6 point scale (Extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, Limited for other reasons or did not do this activity).Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary Score.
|
13.44 units on a scale
Standard Deviation 22.61
|
13.25 units on a scale
Standard Deviation 22.38
|
SECONDARY outcome
Timeframe: Randomization to 180 daysPopulation: All randomized subjects.
Individual component of the primary endpoint of mortality at 180 days after randomization
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Individual Component of the Primary Endpoint- Mortality
|
19 participants
|
16 participants
|
SECONDARY outcome
Timeframe: Randomization to 180 daysPopulation: All randomized subjects.
Individual component of the primary endpoint- Heart Failure hospitalization from randomization to 180 days
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Individual Component of the Primary Endpoint- Heart Failure Hospitalization
|
63 participants
|
50 participants
|
SECONDARY outcome
Timeframe: Baseline to 180 daysPopulation: All randomized subjects.
Individual component of the primary endpoint- time-averaged proportional change in NT-proBNP from baseline to 180 days
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Individual Component of the Primary Endpoint- Time-averaged Proportional Change in NT-proBNP
|
335.81 weighted average of ratio to baseline
Standard Deviation 445.8
|
317 weighted average of ratio to baseline
Standard Deviation 307.64
|
SECONDARY outcome
Timeframe: Baseline to 180 daysPopulation: All randomized subjects.
A rank score based on time to death, time to adjudicated heart failure hospitalization, time to emergency department visit and time-averaged proportional change in NTproBNP through d180. See Outcome Measure 1 for a general description of the outcome derivation.
Outcome measures
| Measure |
Liraglutide
n=154 Participants
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous daily.
Liraglutide: Active Drug
|
Placebo
n=146 Participants
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous daily.
Placebo: Placebo
|
|---|---|---|
|
Global Ranking of Predefined Events
|
144.29 rank
Standard Deviation 87.63
|
157.05 rank
Standard Deviation 85.61
|
Adverse Events
Liraglutide
Placebo
Serious adverse events
| Measure |
Liraglutide
n=154 participants at risk
Increasing dose from 0.6mg, 1.2mg to 1.8mg subcutaneous (SQ) daily.
Liraglutide: Active Drug
|
Placebo
n=146 participants at risk
Placebo dose increasing from 0.6mg, 1.2mg to 1.8 mg subcutaneous (SQ) daily.
Placebo: Placebo
|
|---|---|---|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/154 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
1.4%
2/146 • Number of events 2 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Cardiac disorders
Angina pectoris
|
1.3%
2/154 • Number of events 3 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.00%
0/146 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Gastrointestinal disorders
Gastrointentinal haemorrhage
|
0.00%
0/154 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
1.4%
2/146 • Number of events 2 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.00%
0/154 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
2.1%
3/146 • Number of events 3 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
General disorders
Non-cardiac chest pain
|
1.3%
2/154 • Number of events 2 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Infections and infestations
Diverticulitis
|
1.3%
2/154 • Number of events 2 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.00%
0/146 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Infections and infestations
Cellulitis
|
0.65%
1/154 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.65%
1/154 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Metabolism and nutrition disorders
Dehydration
|
1.3%
2/154 • Number of events 2 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Metabolism and nutrition disorders
Gout
|
0.65%
1/154 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
2.6%
4/154 • Number of events 4 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
2.1%
3/146 • Number of events 4 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
1.3%
2/154 • Number of events 2 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Nervous system disorders
Hepatic Encephalopathy
|
1.3%
2/154 • Number of events 2 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
1.3%
2/154 • Number of events 2 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.00%
0/146 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Vascular disorders
Hypotension
|
2.6%
4/154 • Number of events 4 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.00%
0/146 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Infections and infestations
Influenza
|
1.3%
2/154 • Number of events 2 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.00%
0/146 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Infections and infestations
Pneumonia
|
1.9%
3/154 • Number of events 3 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
2.7%
4/146 • Number of events 5 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Injury, poisoning and procedural complications
Toxicity to various agents
|
0.65%
1/154 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Investigations
International Normalised Ratio Increased
|
1.3%
2/154 • Number of events 2 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.00%
0/146 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Gastrointestinal disorders
Abdominal Pain
|
0.00%
0/154 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
General disorders
Hernia
|
0.00%
0/154 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Infections and infestations
Sepsis
|
0.00%
0/154 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Infections and infestations
Viral Rash
|
0.00%
0/154 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Injury, poisoning and procedural complications
Spinal compression fracture
|
0.00%
0/154 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Metabolism and nutrition disorders
Hyperolmolar Hyperglycaemic State
|
0.00%
0/154 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal Pain
|
0.00%
0/154 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate Cancer
|
0.00%
0/154 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Nervous system disorders
Hypoglycaemic unconsciousness
|
0.00%
0/154 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Pregnancy, puerperium and perinatal conditions
Abortion spontaneous
|
0.00%
0/154 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/154 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
0.68%
1/146 • Number of events 1 • Baseline to day 210.
All serious adverse events documented from baseline to day 210. According to protocol: Non-serious adverse events will not be collected on the eCRF but should be documented in source documents and followed according to local standard of care. Non-serious adverse events were not reported to sponsor, and therefore not reported.
|
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place